Different levels of TGFβ, IL-10, IFNγ and gelatinase A occur in experimental white and black metastases induced by bryostatin 1 or by phorbol ester-treated BL6T murine melanoma cells

Clinical and Experimental Metastasis

Volumn 18, Issue 5, 2000, Pages 361-369

  La Porta, C A M ^a   Comolli, R ^a  

^a Institute of General Pathology   (Italy)

Author keywords

Cytokines; Gelatinase; Melanoma; Metastasis; PKC

Indexed keywords

BRYOSTATIN 1; CYTOKINE; GAMMA INTERFERON; GELATINASE A; INTERLEUKIN 10; LACTATE DEHYDROGENASE; PHORBOL ESTER; PROTEIN KINASE C; TRANSFORMING GROWTH FACTOR BETA; ANTINEOPLASTIC AGENT; LACTONE; MACROLIDE; PHORBOL 13 ACETATE 12 MYRISTATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL CULTURE; CELL PROLIFERATION; CYTOTOXICITY; ENZYME ANALYSIS; EVALUATION; MELANOGENESIS; MELANOMA CELL; METASTASIS; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG EFFECT; GENETICS; LUNG TUMOR; MELANOMA; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTINEOPLASTIC AGENTS; INTERFERON TYPE II; INTERLEUKIN-10; L-LACTATE DEHYDROGENASE; LACTONES; LUNG NEOPLASMS; MACROLIDES; MATRIX METALLOPROTEINASE 2; MELANOMA; MICE; MICE, INBRED C57BL; PROTEIN KINASE C; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TETRADECANOYLPHORBOL ACETATE; TRANSFORMING GROWTH FACTOR BETA;

EID: 0034961259     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1010913907830     Document Type: Article

References (29)

1. Activation of protein kinase C-α isoform in murine melanoma cells with high metastatic potential
2. Angiogenic capacity and lung-colonising potential in vivo is increased in weakly metastatic BI6FI cells and decreased in highly metastatic BL6 cells by phorbol esters
3. Human melanoma metastasis is inhibited following ex vivo treatment with an antisense oligonucleotide to protein kinase C-alpha
4. Overexpression of n-PKCδ in BL6 murine melanoma cells inhibits the proliferative capacity in vitro but enhanced the metastatic potential in vivo
5. Malignant melanoma: Relationship to parameters of differentaition
6. Amelanotic malignant melanoma
7. Regulation of melanogenesis in B 16 mouse melanoma cells by protein kinase C
8. Preclinical evaluation by bryostatin as an anticancer agent against several murine tumor cell lines: In vitro versus in vivo activity
9. Successful treatment of murine melanoma with bryostatin 1
10. A phase I study of intravenous bryostatin 1 in patients with advanced cancer
11. Phase I study bryostatin 1: Assessment of interleukine 6 and tumor factor a induction in vivo
12. Treatment of patients with metastatic melanoma with bryostatin 1 - A phase II study
13. Changes in melanogenesis during the differentiation of chick retinal pigment cells in cell cultures
14. Inhibition of the mitogen-activated protein kinase pathway triggers B 16 melanoma cell differentiation
15. Quantitation of messenger RNA by competitive RT-PCR: A simplified read out assay
16. Cellular activation of mesangial gelatinase A by cytochalasin D is accompanied by enhanced mRNA expression of both gelatinase A and its membrane-associated gelatinase A activator (MT-MMP)
17. Aberrant retention of tyrosinase in the endoplasmic reticulum mediates accelerated degradation of the enzyme and contributes to the differentiated phenotype of amelanotic melanoma cells
18. Diverse manifestations of tumorigenicity and immunogenicity displayed by the poor immunogenic B16-BL6 melanoma transduced with cytokine genes
19. The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: Dissociation of activities using 26-epi-bryostatin 1
20. Transforming growth factor-beta 1 inhibits basal melanogenesis in B16/F10 mouse melanoma cells by increasing the rate of degradation of tyrosinase and tyrosinase-related protein- 1
21. Improved protocol for colorimetric detection of complement-mediated cytotoxicity based on the measurement of cytoplasmic lactate dehydrogenase activity
22. Immune effects of low-dose subcutaneous interleukin 2 in patients with metastatic malignant melanoma
23. Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or gamma interferon
24. Bacillus calmette-guerin plus interleukin-2 and/or granulocyte/macrophage-colony stimulating factor enhances immunocompetent cell production of interferon-gamma which inhibits B16F10 melanoma cell growth in vitro
25. Growth control of melanoma cells and melanocytes by cytokines
26. Interleukine 10 production by human melanoma
27. Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma
28. Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells, potential inhibition of angiogenesis
29. Matrix metalloproteinases in human melanoma cell lines and xenografts: Increased expression of activated matrix metalloproteinases-2 (MMP-2) correlates with melanoma progression